RgIA4 Prevention of Acute Oxaliplatin-Induced Cold Allodynia Requires α9-Containing Nicotinic Acetylcholine Receptors and CD3+ T-Cells
暂无分享,去创建一个
[1] J. McIntosh,et al. Alkaloid ligands enable function of homomeric human α10 nicotinic acetylcholine receptors , 2022, Frontiers in Pharmacology.
[2] O. Kaminuma,et al. Expression and Function of Nicotinic Acetylcholine Receptors in Induced Regulatory T Cells , 2022, International journal of molecular sciences.
[3] A. Nicke,et al. Interaction of α9α10 Nicotinic Receptors With Peptides and Proteins From Animal Venoms , 2021, Frontiers in Cellular Neuroscience.
[4] David John Adams,et al. Analgesic α‐conotoxins modulate native and recombinant GIRK1/2 channels via activation of GABAB receptors and reduce neuroexcitability , 2021, British journal of pharmacology.
[5] J. McIntosh,et al. Discovery of Methylene Thioacetal-Incorporated α-RgIA Analogues as Potent and Stable Antagonists of the Human α9α10 Nicotinic Acetylcholine Receptor for the Treatment of Neuropathic Pain. , 2021, Journal of medicinal chemistry.
[6] J. McIntosh,et al. Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism. , 2021, Journal of medicinal chemistry.
[7] R. Norton,et al. Alkyne-Bridged α-Conotoxin Vc1.1 Potently Reverses Mechanical Allodynia in Neuropathic Pain Models. , 2021, Journal of Medicinal Chemistry.
[8] A. Kavelaars,et al. T Cells as Guardians of Pain Resolution. , 2021, Trends in molecular medicine.
[9] J. McIntosh,et al. Development of Conformationally Constrained α-RgIA Analogues as Stable Peptide Antagonists of Human α9α10 Nicotinic Acetylcholine Receptors. , 2020, Journal of medicinal chemistry.
[10] D. Craik,et al. Critical Residue Properties for Potency and Selectivity of α-Conotoxin RgIA Towards α9α10 Nicotinic Acetylcholine Receptors. , 2020, Biochemical pharmacology.
[11] Stephanie I. Shiers,et al. Quantitative differences in neuronal subpopulations between mouse and human dorsal root ganglia demonstrated with RNAscope in situ hybridization. , 2020, Pain.
[12] R. Su,et al. The α9α10 Nicotinic Acetylcholine Receptor Antagonist αO-Conotoxin GeXIVA[1,2] Alleviates and Reverses Chemotherapy-Induced Neuropathic Pain , 2019, Marine drugs.
[13] V. Apostolopoulos,et al. Oxaliplatin Treatment Alters Systemic Immune Responses , 2019, BioMed research international.
[14] J. McIntosh,et al. Conopeptides [V11L;V16D]ArIB and RgIA4: Powerful Tools for the Identification of Novel Nicotinic Acetylcholine Receptors in Monocytes , 2019, Front. Pharmacol..
[15] P. Dougherty,et al. Beyond symptomatic relief for chemotherapy‐induced peripheral neuropathy: Targeting the source , 2018, Cancer.
[16] D. Servent,et al. α9‐containing nicotinic acetylcholine receptors and the modulation of pain , 2018, British journal of pharmacology.
[17] D. Craik,et al. Structure-Activity Studies Reveal the Molecular Basis for GABAB-Receptor Mediated Inhibition of High Voltage-Activated Calcium Channels by α-Conotoxin Vc1.1. , 2018, ACS chemical biology.
[18] B. Morley,et al. Commentary: Nicotinic Acetylcholine Receptor α9 and α10 Subunits Are Expressed in the Brain of Mice , 2018, Front. Cell. Neurosci..
[19] A. Scope,et al. NKp46 Receptor‐Mediated Interferon‐&ggr; Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis , 2018, Immunity.
[20] L. Basso,et al. T-lymphocyte-derived enkephalins reduce Th1/Th17 colitis and associated pain in mice , 2018, Journal of Gastroenterology.
[21] M. Zucchetti,et al. Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights , 2017, PloS one.
[22] E. Glowatzki,et al. RgIA4 Potently Blocks Mouse α9α10 nAChRs and Provides Long Lasting Protection against Oxaliplatin-Induced Cold Allodynia , 2017, Front. Cell. Neurosci..
[23] W. Padberg,et al. Canonical and Novel Non-Canonical Cholinergic Agonists Inhibit ATP-Induced Release of Monocytic Interleukin-1β via Different Combinations of Nicotinic Acetylcholine Receptor Subunits α7, α9 and α10 , 2017, Front. Cell. Neurosci..
[24] C. Ghelardini,et al. Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain , 2017, Proceedings of the National Academy of Sciences.
[25] D. Goldstein,et al. Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy , 2017, PloS one.
[26] C. Ghelardini,et al. The α9α10 nicotinic receptor antagonist α-conotoxin RgIA prevents neuropathic pain induced by oxaliplatin treatment , 2016, Experimental Neurology.
[27] W. Padberg,et al. Phosphocholine – an agonist of metabotropic but not of ionotropic functions of α9-containing nicotinic acetylcholine receptors , 2016, Scientific Reports.
[28] D. Craik,et al. Cloning, synthesis, and characterization of αO-conotoxin GeXIVA, a potent α9α10 nicotinic acetylcholine receptor antagonist , 2015, Proceedings of the National Academy of Sciences.
[29] K. Vowles,et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis , 2015, Pain.
[30] David John Adams,et al. Novel Mechanism of Voltage-Gated N-type (Cav2.2) Calcium Channel Inhibition Revealed through α-Conotoxin Vc1.1 Activation of the GABAB Receptor , 2015, Molecular Pharmacology.
[31] A. Cesario,et al. Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain , 2014 .
[32] M. J. McIntosh,et al. α-Conotoxin RgIA protects against the development of nerve injury-induced chronic pain and prevents both neuronal and glial derangement , 2014, PAIN®.
[33] Gila Moalem-Taylor,et al. Regulatory T cells attenuate neuropathic pain following peripheral nerve injury and experimental autoimmune neuritis , 2012, PAIN®.
[34] D. Bennett,et al. The role of the immune system in the generation of neuropathic pain , 2012, The Lancet Neurology.
[35] A. Eschalier,et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors , 2011, EMBO molecular medicine.
[36] A. Viola,et al. Differential involvement of α4β2, α7 and α9α10 nicotinic acetylcholine receptors in B lymphocyte activation in vitro. , 2011, The international journal of biochemistry & cell biology.
[37] K. Huth,et al. CD4(+) T-cells are important in regulating macrophage polarization in C57BL/6 wild-type mice. , 2011, Cellular immunology.
[38] Maria Fitzgerald,et al. T-Cell Infiltration and Signaling in the Adult Dorsal Spinal Cord Is a Major Contributor to Neuropathic Pain-Like Hypersensitivity , 2009, The Journal of Neuroscience.
[39] M. Friedlander,et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. , 2009, Brain : a journal of neurology.
[40] R. Baron,et al. Oxaliplatin-induced painful neuropathy – Flicker of hope or hopeless pain? , 2009, Pain.
[41] C. Loprinzi,et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. , 2008, European journal of cancer.
[42] R. Norton,et al. Alpha-RgIA, a novel conotoxin that blocks the alpha9alpha10 nAChR: structure and identification of key receptor-binding residues. , 2008, Journal of molecular biology.
[43] P. Kisielow,et al. Identification of Genes Involved in Positive Selection of CD4+8+ Thymocytes: Expanding the Inventory , 2007, Immunological investigations.
[44] J. McIntosh,et al. Molecular mechanism for analgesia involving specific antagonism of α9α10 nicotinic acetylcholine receptors , 2006, Proceedings of the National Academy of Sciences.
[45] J. McIntosh,et al. α-RgIA: A Novel Conotoxin That Specifically and Potently Blocks the α9α10 nAChR†,‡ , 2006 .
[46] K. Gayler,et al. Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones , 2005, Brain Research.
[47] R. J. Cersosimo. Oxaliplatin-Associated Neuropathy: A Review , 2005, The Annals of pharmacotherapy.
[48] G. Moalem,et al. T lymphocytes play a role in neuropathic pain following peripheral nerve injury in rats , 2004, Neuroscience.
[49] R. Ferris,et al. Characterization of the human nicotinic acetylcholine receptor subunit alpha (alpha) 9 (CHRNA9) and alpha (alpha) 10 (CHRNA10) in lymphocytes. , 2004, Life sciences.
[50] S. Heinemann,et al. α10: A determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[51] Jacques Barhanin,et al. Role of α9 Nicotinic ACh Receptor Subunits in the Development and Function of Cochlear Efferent Innervation , 1999, Neuron.
[52] S. Heinemann,et al. α9: An acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells , 1994, Cell.